近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Xiao X, Feng J, Ma J, Xia X, Liu X, Zhang J, Ding C, Pang X*, Zhang A*. Design, synthesis and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRASG12D inhibitors. J Med Chem. 2023 Oct (In press).
Liu Y, Hu L, Wu Z, Yuan K, Hong G, Lian Z, Feng J, Li N, Li D, Wong J, Chen J, Liu M, He J*, Pang X*. Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons. Nat Commun. 2023 Jul 15;14(1):4225 (Featured article).
He P, Feng J, Xia X, Sun Y, He J, Guan T, Peng Y, Zhang X, Liu M, Pang X*, Chen Y*. Discovery of a potent and oral complex I OXPHOS inhibitor that abrogates tumor growth and circumvents MEKi resistance. J Med Chem. 2023 May 11;66(9):6047-6069.
Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, Wang L, Wang C, Zhang X*, Pang X*. Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene. 2023 May;42(20):1620-1633.
Feng J, Lian Z, Xia X, Lu Y, Hu K, Zhang Y, Liu Y, Hu L, Yuan K, Sun Z*, Pang X*. Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer. Acta Pharm Sin B. 2023 Mar 11; 13(3):1145-1163 (Cover story).
Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, Chen J, Lian Z, Chen Y, Hu K, Chen Z, Cai Z, Liu M, Pang X*. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer. J Clin Invest. 2022 Nov 15;132(22):e161308.
Liu Y, Feng J, Yuan K, Wu Z, Hu L, Lu Y, Li K, Guo J, Chen J, Ma C*, Pang X*. The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress. eLife. 2022 May 3;11:e69255.
Jiang B, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang H, Pang X*, Yu L*. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitor. Eur J Med Chem. 2022 Jan 5;227:113893.
Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X*. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors. J Clin Invest. 2021 Jan 4;131(1):e133090
Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C*, Sun Z*, Pang X*. Blocking STAT3 by Pyrvinium Pamoate Causes Metabolic Lethality in KRAS-mutant Lung Cancer. Biochem Pharmacol. 2020 Jul;177:113960.
Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y*, Liu M*, Pang X*. Suppression of the SLC7A11/glutathione Axis Causes Synthetic Lethality in KRAS-mutant Lung Adenocarcinoma. J Clin Invest. 2020 Apr 1;130(4):1752-1766.
Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M, Cheng F*, Zhao Z*, Pang X*. Repurposing Sertraline Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib by Inducing Autophagy. JCI Insight. 2018 Jun 7;3(11):e98921.
Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X*. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Br J Pharmacol. 2017 Oct;174(20):3608-3622.
Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X*, Liu M*. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun. 2016 May 19;7:11363.
京公网安备 11010802027423号